Shopping Cart
Remove All
Your shopping cart is currently empty
Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | In Stock | In Stock | |
| 5 mg | $483 | In Stock | In Stock | |
| 10 mg | $692 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
| Description | Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections. |
| Targets&IC50 | RSV A strains:0.1 nM |
| In vitro | Gontivimab (0-100,000 nM) exhibited antiviral effects with IC50 values of 0.1 nM and 0.4 nM against RSV-A and RSV-B 18537 strains, respectively.[1] Gontivimab binds to antigenic site II of the F protein.[1] Gontivimab binds to antigenic site II of the F protein.[1] |
| In vivo | Gontivimab (1-68 mg/kg; administered intranasally or by nebulization) reduces RSV load in the nasal cavity and lungs of rats.[1] Gontivimab has been shown to reduce RSV load in the nasal cavity and lungs of rats. [1] |
| Synonyms | VR-465, VR465, ALX-0171, ALX0171 |
| Cas No. | 1257358-38-5 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.